Share Email Print

Proceedings Paper

The photosensitizer talaporfinum caused microvascular embolization for photodynamic therapy
Author(s): Liming Li; Katsuo Aizawa
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Photodynamic therapy (PDT) has been evolving rapidly in the recent years. A second-generation Photosensitizer mono-1-aspartyl chlorine 6 (Talaporfin / Npe6 / ME2906, Japan Meiji Seika, Ltd.) has been sanctified for the lung cancer clinical PDT by the Japan Ministry of Health, Labor and Welfare. In this paper, Talaporfin was injected to the implant cancer of a mouse a Talaporfin dose of 5mg/kg through intravenous. After 6 hours, the fluorescence images of the mouse were observed with a microscope and a 664 nm diode laser. Effects of therapy were clarified using the different irradiation energies of the laser (50, 100, 200 J/cm2). Both in plasma and in cancer, the concentrations of Talaporfin were analyzed using High Performance Liquid Chromatography (HPLC). Authors find that the higher concentrations of Talaporfin in plasma, the better PDD effect. It is experimentally verified that local microvascular embolisms in the cancer are formed for photodynamic therapy after the Talaporfin injection and the laser irradiation.

Paper Details

Date Published: 11 September 2006
PDF: 4 pages
Proc. SPIE 5967, 2004 Shanghai International Conference on Laser Medicine and Surgery, 59670V (11 September 2006); doi: 10.1117/12.639220
Show Author Affiliations
Liming Li, Chitose Institute of Science and Technology (Japan)
Katsuo Aizawa, Tokyo Medical Univ. (Japan)

Published in SPIE Proceedings Vol. 5967:
2004 Shanghai International Conference on Laser Medicine and Surgery
Jing Zhu, Editor(s)

© SPIE. Terms of Use
Back to Top